lonafarnib has been researched along with alendronate in 1 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (alendronate) | Trials (alendronate) | Recent Studies (post-2010) (alendronate) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 4,096 | 731 | 1,724 |
| Protein | Taxonomy | lonafarnib (IC50) | alendronate (IC50) |
|---|---|---|---|
| Chain A, farnesyl pyrophosphate synthase | Trypanosoma cruzi | 147 | |
| Farnesyl pyrophosphate synthase | Homo sapiens (human) | 0.7523 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crovella, S; De Leo, L; Decorti, G; Marcuzzi, A; Pontillo, A; Tommasini, A | 1 |
1 other study(ies) available for lonafarnib and alendronate
| Article | Year |
|---|---|
The farnesyltransferase inhibitors tipifarnib and lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency.
Topics: Acyclic Monoterpenes; Alendronate; Animals; Anti-Inflammatory Agents; Cell Line; Child; Child, Preschool; Cholesterol; Cytokines; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Inflammation Mediators; Lovastatin; Male; Mevalonate Kinase Deficiency; Mice; Monocytes; Phosphotransferases (Alcohol Group Acceptor); Piperidines; Polyenes; Polyisoprenyl Phosphates; Polyunsaturated Alkamides; Pyridines; Quinolones; Terpenes | 2011 |